Supernus terminates UBS credit line ahead of Indivior merger close

Supernus Pharmaceuticals, Inc. disclosed in an 8-K dated October 26, 2026 that it terminated its credit agreement with UBS Bank USA on October 20, 2026. The agreement, dated February 8, 2023, had set up an uncommitted, demand revolving line of credit between the company and the bank.¹

The company said the move was tied to its pending merger. Supernus terminated the UBS facility ahead of closing its previously disclosed combination with Indivior Pharmaceuticals, Inc., which is structured under a merger agreement dated August 1, 2026, and in anticipation of a new senior secured credit facility the combined company plans to put in place once that deal closes.¹

Under the terms of the original facility, the line of credit had been backed by a pledge of a securities collateral account held at UBS, along with related assets.¹

At the time the agreement ended, there was nothing drawn against it. No advances, letters of credit, or other borrowings were outstanding under the facility when it was terminated, and Supernus did not pay any early termination fees.¹ As part of the wind-down, UBS released its security interests in the collateral that had backed the line.¹

The filing was signed by Timothy C. Dec, Senior Vice President and Chief Financial Officer, on October 26, 2026. The 8-K does not provide a specific closing date for the Indivior merger beyond referencing the August 1, 2026 merger agreement and the anticipated new credit facility to follow at closing.